We hold our clinical research to the highest scientific and ethical standards. We execute on these standards through our rigorous discovery process and our adherence to good clinical practices and clinical trial standards set by the FDA, EMA, PMDA and other international regulatory bodies. Incyte is committed to acting ethically and responsibly and applying high standards of care when conducting preclinical research both internally and at third-party institutions. Incyte’s facility is AAALAC International accredited, and wherever possible, we work with third parties accredited by AAALAC International. We focus on data transparency by presenting study data, regardless of outcome, at appropriate medical meetings and in peer-reviewed journals. To learn more, please see our Clinical Trial Transparency, Data Sharing and Disclosure Practices here.
Our Focus on New Therapies
Our portfolio speaks to our commitment to improving the treatment of serious diseases like cancer and inflammatory and autoimmune diseases.
In oncology, we have 3 discovery platforms: small molecule, monoclonal antibody, and bispecific antibody capabilities. We believe that this multifaceted approach positions us well as we seek to utilize these different treatment modalities to evaluate development candidates across a diverse spectrum of therapeutic targets.
The goal of Incyte’s Inflammation and Autoimmunity (IAI) development group is to identify, target and modulate immunological pathways driving uncontrolled inflammation and the destruction of the body’s own cells and tissues. In doing so, we hope to restore normal immune function to bring the body closer to homeostasis. Our IAI team utilizes their broad immunological understanding of disease and cross functional knowledge of our programs to identify innovative approaches to treating inflammatory and autoimmune diseases.
As the effort to bring transformative treatments to patients is a significant undertaking, we are committed to partnering with companies, universities, and research institutions in order to share knowledge, resources, and ideas that may best benefit patients.
lncyte may also provide our investigational products and/or financial support for independent research by third parties in therapeutic areas of interest. We are committed to ensuring that requests for investigator-initiated research (IIRs) are submitted, reviewed, and, if approved, conducted and funded in a standardized and consistent manner. Incyte seeks to ensure that our interactions with study investigators comply with all applicable legal and ethical standards and obligations.
Our commitment to patients through scientific excellence has resulted in FDA approved products, including for the treatment of diseases where there were no prior therapies approved. Jakafi® (ruxolitinib) was the first FDA-approved JAK inhibitor for any indication and was the first FDA-approved product in all three of its current indications. Pemazyre™ (pemigatinib) was also approved1 by the FDA in an indication where there were no approved therapies for patients.
We acquired the right to Iclusig® (ponatinib) through an exclusive license from Takeda Pharmaceuticals International in the European Union and 29 other countries, including Switzerland, Norway, Turkey, Israel and Russia. Beyond our in-house development portfolio, Incyte scientists discovered two additional approved medicines, Olumiant® (baricitinib), developed and commercialized by our partner Eli Lilly, and Tabrecta™ (capmatinib), developed and commercialized by our partner Novartis.
Because our commitment to patients is our top priority, a significant portion of our revenue is reinvested back into R&D to support the discovery and development of new therapies for patients in need.